See more : Raysum Co., Ltd. (8890.T) Income Statement Analysis – Financial Results
Complete financial analysis of BioLargo, Inc. (BLGO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioLargo, Inc., a leading company in the Chemicals industry within the Basic Materials sector.
You may be interested
- NewAge, Inc. (NBEV) Income Statement Analysis – Financial Results
- Boryung Corporation (003850.KS) Income Statement Analysis – Financial Results
- Nippon Carbon Co., Ltd. (NCRBF) Income Statement Analysis – Financial Results
- teno. Holdings Company Limited (7037.T) Income Statement Analysis – Financial Results
- NEFAZ Publicly Traded Company (NFAZ.ME) Income Statement Analysis – Financial Results
BioLargo, Inc. (BLGO)
About BioLargo, Inc.
BioLargo, Inc. invents, develops, and commercializes various platform technologies. The company's technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. It holds various issued patents, maintains a pipeline of products, and provides full-service environmental engineering services. The company's products include Advanced Oxidation system, a water treatment device that generates a series of oxidative and energetic species of iodine and other molecules; Aqueous Electrostatic Concentrator, a water treatment system that removes per- and poly-fluoroalkyl substances from water; CupriDyne Clean industrial products, which reduce and eliminate tough odors and volatile organic compounds in various industrial settings; and advanced wound care products. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.23M | 5.88M | 2.53M | 2.43M | 1.86M | 1.36M | 516.21K | 281.11K | 127.58K | 111.55K | 167.95K | 65.54K | 156.19K | 156.76K | 138.13K | 0.00 | 80.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 749.84K | 833.54K | 1.88M | 2.39M | 1.93M | 2.50M | 1.30M | 4.50M | 7.70M | 9.40M | 9.80M | 6.70M |
| Cost of Revenue | 6.08M | 3.03M | 1.43M | 1.20M | 945.00K | 743.00K | 322.72K | 105.88K | 62.07K | 56.00K | 29.66K | 39.78K | 44.76K | 125.48K | 114.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.29K | 0.00 | 119.41K | 119.18K | 22.41K | 0.00 | 0.00 | 0.00 | 0.00 | 5.10M | 6.40M | 7.80M | 7.70M | 5.20M |
| Gross Profit | 6.15M | 2.86M | 1.10M | 1.23M | 916.00K | 621.00K | 193.50K | 175.23K | 65.52K | 55.55K | 138.29K | 25.76K | 111.43K | 31.28K | 23.58K | 0.00 | 80.00K | 0.00 | 0.00 | 0.00 | -20.29K | 0.00 | 630.43K | 714.35K | 1.86M | 2.39M | 1.93M | 2.50M | 1.30M | -600.00K | 1.30M | 1.60M | 2.10M | 1.50M |
| Gross Profit Ratio | 50.32% | 48.56% | 43.58% | 50.49% | 49.22% | 45.53% | 37.48% | 62.34% | 51.35% | 49.80% | 82.34% | 39.30% | 71.34% | 19.95% | 17.07% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 84.08% | 85.70% | 98.81% | 100.00% | 100.00% | 100.00% | 100.00% | -13.33% | 16.88% | 17.02% | 21.43% | 22.39% |
| Research & Development | 2.28M | 1.32M | 1.37M | 1.34M | 1.47M | 1.72M | 1.63M | 1.38M | 684.55K | 642.92K | 742.25K | 126.02K | 99.50K | 100.56K | 170.12K | 113.75K | 131.35K | 129.52K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 6.14M | 5.26M | 4.43M | 0.00 | 3.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.97M | 2.60M | 1.77M | 1.73M | 1.69M | 1.38M | 1.10M | 1.40M | 1.60M | 1.60M | 1.10M | 500.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 246.00K | 246.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.06M | 6.73M | 6.17M | 7.47M | 6.14M | 5.26M | 4.43M | 3.71M | 3.55M | 2.79M | 2.00M | 4.61M | 3.17M | 4.12M | 3.96M | 4.83M | 2.99M | 1.63M | 944.81K | 971.94K | 2.34M | 2.16M | 3.97M | 2.60M | 1.77M | 1.73M | 1.69M | 1.38M | 1.10M | 1.40M | 1.60M | 1.60M | 1.10M | 500.00K |
| Other Expenses | 0.00 | -74.00K | -55.00K | -137.00K | -218.00K | 73.00K | 71.13K | 13.74K | 10.92K | 10.92K | 10.92K | 5.43K | 7.87K | 9.56K | 1.12M | 1.11M | 738.14K | 0.00 | 0.00 | 0.00 | 8.55K | -661.87K | 3.45M | 268.46K | -1.32M | 258.13K | 186.53K | 189.35K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 10.34M | 7.98M | 7.48M | 8.67M | 7.39M | 6.88M | 6.09M | 5.11M | 4.25M | 3.45M | 2.76M | 4.74M | 3.27M | 4.23M | 5.25M | 6.05M | 3.86M | 1.76M | 944.81K | 971.94K | 2.35M | 1.50M | 7.42M | 2.86M | 453.95K | 1.99M | 1.87M | 1.57M | 1.20M | 1.40M | 1.60M | 1.60M | 1.10M | 500.00K |
| Cost & Expenses | 16.42M | 11.00M | 8.91M | 9.88M | 8.34M | 7.62M | 6.41M | 5.22M | 4.31M | 3.50M | 2.79M | 4.78M | 3.32M | 4.36M | 5.36M | 6.05M | 3.86M | 1.76M | 944.81K | 971.94K | 2.37M | 1.50M | 7.54M | 2.98M | 476.36K | 1.99M | 1.87M | 1.57M | 1.20M | 6.50M | 8.00M | 9.40M | 8.80M | 5.70M |
| Interest Income | 0.00 | 53.00K | 234.00K | 1.92M | 4.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 135.53K | 35.96K | 0.00 | 153.51K | 0.00 | 255.93K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 91.00K | 53.00K | 234.00K | 1.92M | 4.00M | 3.49M | 3.86M | 3.13M | 994.67K | 348.15K | 281.59K | 616.35K | 793.26K | 1.67M | 1.63M | 1.15M | 1.56M | 344.88K | 242.49K | 250.70K | 344.83K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 45.00K | 20.00K | 58.00K | 65.00K | 50.00K | 29.84K | 15.89K | 10.92K | 10.92K | 10.92K | 5.43K | 7.87K | 9.56K | 1.12M | 1.11M | 738.14K | -796.55K | 246.10K | -4.60K | 660.30K | 9.94K | 176.10K | 268.46K | 197.19K | 258.13K | 186.53K | 189.35K | -100.00K | -300.00K | -100.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -4.19M | -5.10M | -6.70M | -7.83M | -7.44M | -7.23M | -5.73M | -4.93M | -4.07M | -3.38M | -2.61M | -4.71M | -3.15M | -4.19M | -4.11M | -5.00M | -3.05M | -2.56M | -698.70K | -967.34K | -1.71M | -1.54M | -2.77M | -4.46M | 1.60M | 664.46K | 245.16K | 1.12M | -100.00K | -2.30M | -400.00K | -200.00K | 1.00M | 1.00M |
| EBITDA Ratio | -34.23% | -85.16% | -248.83% | -299.22% | -341.21% | -449.49% | -1,136.19% | -1,749.86% | -3,346.62% | -3,030.56% | -1,553.32% | -7,189.59% | -2,018.88% | -2,751.20% | 3,370.18% | 0.00% | -3,918.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -881.77% | -225.65% | 246.39% | 27.78% | 12.68% | 44.96% | -7.69% | -51.11% | -5.19% | -2.13% | 10.20% | 14.93% |
| Operating Income | -4.19M | -5.12M | -6.38M | -7.45M | -6.48M | -6.41M | -5.90M | -4.93M | -4.18M | -3.39M | -2.62M | -4.72M | -3.16M | -4.20M | -14.01M | -6.05M | -3.78M | -1.76M | -944.81K | -971.94K | -2.37M | -1.50M | -6.79M | -2.15M | -112.29K | 406.32K | 58.63K | 935.07K | 100.00K | -2.00M | -300.00K | -200.00K | 1.00M | 1.00M |
| Operating Income Ratio | -34.23% | -87.00% | -252.11% | -306.17% | -348.09% | -470.09% | -1,141.98% | -1,755.52% | -3,277.49% | -3,040.35% | -1,559.82% | -7,197.88% | -2,023.91% | -2,678.33% | -10,138.78% | 0.00% | -4,730.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -905.25% | -257.85% | -5.98% | 16.99% | 3.03% | 37.39% | 7.69% | -44.44% | -3.90% | -2.13% | 10.20% | 14.93% |
| Total Other Income/Expenses | -449.00K | 61.00K | -458.00K | -2.12M | -4.74M | -4.28M | -3.65M | -3.14M | -895.55K | -348.15K | -281.59K | -616.35K | -793.26K | -1.54M | -8.76M | 59.99K | -1.48M | 796.55K | -246.10K | -246.10K | -344.83K | 6.74K | 121.94K | 35.96K | -1.41M | 153.51K | 222.88K | 255.93K | 200.00K | 200.00K | 100.00K | 300.00K | 0.00 | -1.00M |
| Income Before Tax | -4.64M | -5.13M | -6.89M | -9.70M | -11.44M | -10.70M | -9.55M | -8.07M | -5.08M | -3.74M | -2.90M | -5.33M | 0.00 | -4.07M | -22.77M | -5.99M | -5.26M | -965.82K | -1.19M | -1.22M | -2.71M | -1.49M | -6.65M | -2.11M | -1.52M | 559.83K | 281.51K | 1.19M | 300.00K | -1.80M | -200.00K | 300.00K | 0.00 | 0.00 |
| Income Before Tax Ratio | -37.90% | -87.22% | -272.38% | -398.85% | -614.72% | -784.16% | -1,849.34% | -2,872.35% | -3,979.42% | -3,352.46% | -1,727.49% | -8,138.27% | 0.00% | -2,599.36% | -16,482.26% | 0.00% | -6,574.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -887.18% | -253.54% | -80.78% | 23.40% | 14.56% | 47.62% | 23.08% | -40.00% | -2.60% | 3.19% | 0.00% | 0.00% |
| Income Tax Expense | 13.00K | -636.00K | 483.00K | 766.00K | 3.31M | -790.00K | 3.43M | 2.89M | 874.50K | -47.45K | -372.92K | 0.00 | 793.26K | 1.54M | 10.39M | 1.09M | 1.48M | 344.88K | -3.61K | 250.70K | 4.91M | 3.44M | 0.00 | 3.47K | -11.54K | 196.71K | 103.68K | 554.64K | -100.00K | -100.00K | -100.00K | 100.00K | -1.00M | -900.00K |
| Net Income | -3.50M | -4.50M | -7.38M | -10.47M | -14.75M | -10.22M | -9.12M | -7.84M | -5.06M | -3.69M | -2.53M | -5.33M | -3.95M | -5.74M | -15.61M | -7.14M | -5.26M | -1.31M | -1.19M | -1.22M | -7.62M | -4.94M | -6.65M | -2.12M | -1.51M | 531.12K | 261.83K | 968.36K | -300.00K | -1.70M | -100.00K | 200.00K | 1.00M | 900.00K |
| Net Income Ratio | -28.65% | -76.41% | -291.47% | -430.35% | -792.53% | -749.34% | -1,766.19% | -2,788.89% | -3,962.92% | -3,309.92% | -1,505.44% | -8,138.27% | -2,531.80% | -3,663.12% | -11,302.54% | 0.00% | -6,574.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -887.18% | -253.96% | -80.16% | 22.20% | 13.54% | 38.72% | -23.08% | -37.78% | -1.30% | 2.13% | 10.20% | 13.43% |
| EPS | -0.01 | -0.02 | -0.03 | -0.05 | -0.10 | -0.08 | -0.09 | -0.09 | -0.06 | -0.05 | -0.03 | -0.08 | -0.07 | -0.13 | -0.37 | -0.17 | -0.18 | -0.48 | -0.55 | -0.66 | -6.25 | -12.61 | -39.08 | -15.72 | -11.43 | 4.00 | 2.27 | 7.25 | -2.27 | -12.88 | -0.76 | 1.52 | 7.58 | 6.82 |
| EPS Diluted | -0.01 | -0.02 | -0.03 | -0.05 | -0.10 | -0.08 | -0.09 | -0.09 | -0.06 | -0.05 | -0.03 | -0.08 | -0.07 | -0.13 | -0.37 | -0.17 | -0.18 | -0.48 | -0.55 | -0.66 | -6.25 | -12.61 | -39.08 | -15.72 | -11.43 | 4.00 | 2.27 | 7.25 | -2.27 | -12.88 | -0.76 | 1.52 | 7.58 | 6.82 |
| Weighted Avg Shares Out | 285.96M | 268.30M | 247.20M | 195.99M | 152.09M | 122.00M | 98.94M | 87.94M | 84.11M | 80.02M | 72.95M | 63.75M | 55.71M | 45.82M | 42.66M | 41.62M | 28.79M | 2.74M | 2.16M | 1.84M | 1.22M | 391.66K | 170.24K | 134.69K | 131.84K | 131.84K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K |
| Weighted Avg Shares Out (Dil) | 285.96M | 268.30M | 247.20M | 195.99M | 152.09M | 122.00M | 98.94M | 87.94M | 84.11M | 80.02M | 72.95M | 63.75M | 55.71M | 45.82M | 42.66M | 41.62M | 28.79M | 2.74M | 2.16M | 1.84M | 1.22M | 391.66K | 170.24K | 134.69K | 131.84K | 131.84K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K |
BioLargo reports rising consolidated 3Q revenue on strong engineering division growth
BioLargo Inc said it saw a jump in consolidated revenue during its third quarter. For the three months ended September 30, 2021, the company said it generated $712,000, a 7% year-over-year increase.
BioLargo Q3 2021 Earnings Results Webcast and Conference Call on Wednesday, November 17, 2021 - 11:00 AM Eastern Time
WESTMINSTER, CA / ACCESSWIRE / November 15, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced it will host an investor webcast and conference call on Wednesday, November 17, 2021, at 8:00 am...
BioLargo says peer-reviewed paper confirms “unprecedented performance” of its AOS water treatment technology
BioLargo Inc has announced the publication of a peer-reviewed article confirming that its water treatment technology, the Advanced Oxidation System (AOS), generates highly energetic iodine molecules. The company said the article establishes the foundational scientific principles about why the AOS...
Peer-Reviewed Paper Explains Unprecedented Performance of BioLargo's AOS Water Treatment Technology
WESTMINSTER, CA / ACCESSWIRE / October 4, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced the publication of an important peer-reviewed article confirming that its innovative water treatment technology, the Advanced...
BioLargo boss says company is close to unlocking the potential of its technologies in wide-ranging update
BioLargo Inc said it was "very close to unlocking the potential" of its technologies, as the cleantech group outlined key strategic partnerships and initiatives, aimed at expanding the firm's commercial reach. In a wide-ranging letter to stockholders, CEO Dennis Calvert...
Letter to Stockholders: BioLargo Positions for Expansive Commercial Reach Through Strategic Partnerships
WESTMINSTER, CA / ACCESSWIRE / September 30, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, released a "Letter to Stockholders" discussing the development of several key strategic partnerships and other business initiatives...
BioLargo's Groundbreaking Technology to Eliminate the Presence of Forever Chemicals in Drinking Water
A bipartisan coalition of the U.S. House of Representatives in July helped pass the “PFAS Action Act of 2021,” which would establish a national drinking water standard for per- and polyfluoroalkyl substances (PFAS) contamination. The bill would enable the Environmental...
BioLargo to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021
WESTMINSTER, CA / ACCESSWIRE / September 8, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, will present at the H.C. Wainwright 23rd Annual Global Investment Conference.
BioLargo introduces new PFAS testing and treatment system selection program
BioLargo, Inc a clean water technology company has launched a new service testing customer water to detect per- and polyfluoroalkyl substances (PFAS) contamination levels. The new service will also advise and administer treatment equipment options to meet federal, state and...
BioLargo's Tonya Chandler to Present with Expert Panel at Sustain SoCal's Water Solutions 6 Web Conference on August 26, 2021
WESTMINSTER, CA / ACCESSWIRE / August 25, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced its participation in Water Solutions 6, the sixth annual water innovation focused conference run by Sustain...
Source: https://incomestatements.info
Category: Stock Reports